RxDoctor Payments DataLook up a doctor →

Stanley Shadid, MD

Family Medicine · Edmond, OKNPI 1386904183

Payments from drug & device makers

$362,902in general payments, 2019–2025

Across 1,097 payments — averaging $330.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$348K
  • Eli Lilly$5K
  • Genentech USA, Inc.$3K
  • AbbVie$835
  • Pfizer$596
  • Amgen$523
  • plus $5K from 47 others

What the payments were for

  • Consulting fees$14,2194%
  • Speaking & faculty fees$300,15883%
  • Travel & lodging$36,36710%
  • Food & beverage$12,0723%
  • Education$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362,902 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$230,389
Medicare patients
662
Services billed
8,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide179$225,049
Synjardy XrEmpagliflozin/Metformin Hcl78$70,973
TrulicityDulaglutide40$49,862
OzempicSemaglutide28$29,748
EliquisApixaban36$26,830
JardianceEmpagliflozin16$24,788
JanumetSitagliptin Phos/Metformin Hcl18$19,298
WegovySemaglutide13$17,511
MyrbetriqMirabegron16$17,091
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,227
KerendiaFinerenone14$12,886
SynjardyEmpagliflozin/Metformin Hcl12$10,039
Breo ElliptaFluticasone/Vilanterol20$7,737
Spiriva RespimatTiotropium Bromide13$6,979
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen144$5,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$347,722$274,910219 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Spiriva Respimat$449$112,779119 claims
Novo NordiskOzempic, Wegovy$378$47,25941 claims
PfizerEliquis, Dilantin$596$28,51947 claims
MerckJanumet, Belsomra$49$24,27829 claims
GSKTrelegy Ellipta, Breo Ellipta$214$23,96541 claims
Astellas Pharma US IncMyrbetriq$77$17,09116 claims
BayerKerendia$374$12,88614 claims
AstraZenecaSymbicort$418$2,89811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →